CUV 1.27% $14.36 clinuvel pharmaceuticals limited

nasdaq down heavily

  1. 365 Posts.
    The bio tech stocks have had a very good run of recent time and a number of companies without revenue but potential have cashed in on the run by getting placements away.

    This keeps them alive whilst they get to see what they are working on is of commercial benefit.

    The trap can be if the sector loses its sizzle and there is a new brigade of stockholders sitting on a profit without the patience these types of stocks require.

    In hot markets they are great daytrade stocks in softening markets you need to believe in the long term story.

    Those who remember the dot comm boom bust will agree,most who are traders and are long will probably poo hoo this as they did with davnet,sausage software need i go on.

    In this case stocks like EPT,VCR,PRR are three I am watching for pull backs below the placement prices to look for a trade.

    This is 50c with EPT who were in there 20s only 2 months ago ,37c with PRR (they also have options expiring soon which whilst they are at a premium can add selling pressure ) and have come up from the high 20s as well.The VCR rights issue price Is 2.25.

    I am not a broker so do your own DD ,thisis just my opinion after watching the Nassie run hard for the last few months and now 2 morings in a row have sizeable pull backs .

    it just reminds of me of history of the nasdaq fall previously ,and history on markets does often can back to repeat.
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
(20min delay)
Last
$14.36
Change
0.180(1.27%)
Mkt cap ! $719.8M
Open High Low Value Volume
$14.08 $14.60 $14.03 $1.210M 84.62K

Buyers (Bids)

No. Vol. Price($)
1 209 $14.27
 

Sellers (Offers)

Price($) Vol. No.
$14.38 417 1
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
$14.37
  Change
0.180 ( 1.60 %)
Open High Low Volume
$14.45 $14.49 $14.05 9640
Last updated 15.59pm 29/03/2024 ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.